Login to Your Account



Is PDL's Model Paying Off? Cash Payments to Shareholders Soon

By Jennifer Boggs


Thursday, October 29, 2009
PDL BioPharma Inc., which promised significant returns to shareholders since adopting an unusual royalty-collecting business model following last year's spinoff of its R&D division, has opted to monetize a percentage of its antibody royalties from Genentech Inc. products to return a special cash dividend by year-end. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription